Eiger BioPharmaceuticals Inc (NASDAQ: EIGR) announced the publication of data from the investigator-sponsored Phase 3 TOGETHER study in patients with COVID-19 in the New England Journal of Medicine.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results